#TargetedOncology
LightNews LightNews
oncodaily.bsky.social
Excited to have another therapeutic option to treat advanced HR+ breast cancer - Stephanie Graff
@drsgraff.bsky.social
@fda.gov

oncodaily.com/insight/step...

#BreastCancer #Cancer #DatopotumabDeruxtecan #FDA #HRpositiveBreastCancer #OncoDaily #Oncology #Health #TargetedOncology #Medicine
Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer - OncoDaily
Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer / Breast Cancer, cancer, Datopotumab deruxtecan, FDA, HR+
oncodaily.com
January 19, 2025 at 4:54 PM
oncodaily.bsky.social
Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

oncodaily.com/science/bisp...

#AdvancedBreastCancer #ColorectalCancer #M701 #GastricCancer #LungCancer #OvarianCancer #Antibody #ASCO24 #BispecificAntibody #Catumaxomab #EpCAM #ESMO #Immunotherapy#TargetedOncology
Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites - OncoDaily
Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites / Advanced Breast Cancer, advanced cancer, advanced colorectal cancer, Advanced
oncodaily.com
December 12, 2024 at 3:41 PM
scri.com
🚀 Big news from SCRI! Dr. David Spigel presented results: Durvalumab shows a 27% reduction in death risk & a 22.5-month median survival boost in our global trial! Watch the video below to learn more. #TargetedOncology #ClinicalTrials #SCRI
www.targetedonc.com/view/adriati...
ADRIATIC Study Shows Durvalumab Boosts Survival in Limited-Stage SCLC
David Spigel, MD, discusses the findings from and methodology behind the ADRIATIC study of durvalumab as consolidation therapy for patients with limited-stage small cell lung cancer.
www.targetedonc.com
February 26, 2025 at 7:40 PM